Background: Active medical-product-safety surveillance systems are being developed to monitor many products and outcomes simultaneously in routinely collected longitudinal electronic healthcare data. These systems will rely on algorithms to generate alerts about potential safety concerns. Methods: We compared the performance of 5 classes of algorithms in simulated data using a sequential matched-cohort framework, and applied the results to 2 electronic healthcare databases to replicate monitoring of cerivastatin-induced rhabdomyolysis. We generated 600,000 simulated scenarios with varying expected event frequency in the unexposed, alerting threshold, and outcome risk in the exposed, and compared the alerting algorithms in each scenario type using an event-based performance metric. Results: We observed substantial variation in algorithm performance across the groups of scenarios. Relative performance varied by the event frequency and by user-defined preferences for sensitivity versus specificity. Type I error-based statistical testing proce-
dures achieved higher event-based performance than other approaches in scenarios with few events, whereas statistical process control and disproportionality measures performed relatively better with frequent events. In the empirical data, we observed 6 cases of rhabdomyolysis among 4294 person-years of follow-up, with all events occurring among cerivastatin-treated patients. All selected algorithms generated alerts before the drug was withdrawn from the market. Conclusions: For active medical-product-safety monitoring in a sequential matched cohort framework, no single algorithm performed best in all scenarios. Alerting algorithm selection should be tailored to particular features of a product-outcome pair, including the expected event frequencies and trade-offs between false-positive and false-negative alerting.
(Epidemiology 2012; 23: 238 -246) T he Sentinel Initiative ("Sentinel") is intended to improve the way in which the US Food and Drug Administration (FDA) assesses medical product safety, by enabling near real-time surveillance of medical products and their outcome in routine care. 1, 2 "Sentinel" will complement passive safetymonitoring systems, such as FDA's Adverse Event Reporting System, by leveraging electronic healthcare data that are routinely and prospectively collected 3 and that are commonly used for drug-safety research. 4, 5 The main objective of active medical-product-safety monitoring is to alert stakeholders about which productoutcome associations warrant further attention. Two broad types of monitoring activities within electronic healthcare data can generate such alerts. Signal detection (or "all-byall") activities involve mining electronic healthcare data for nonprespecified associations among all possible product and outcome combinations. Targeted safety monitoring involves examining prespecified product and outcome pairs, typically shortly after marketing authorization and informed by preapproval data or by knowledge of similar compounds. FDA's Mini-Sentinel pilot has initially focused on the latter approach, 3 which FDA refers to as "signal refinement."
Whether evaluating prespecified or nonprespecified outcomes, confounding and other biases inherent in observa-tional data threaten the validity of monitoring activities. 2 However, when evaluating prespecified outcomes, prospective medical-product monitoring can resemble ordinary epidemiologic studies, 6 enabling the use of various design and analytic techniques to minimize false-positive and falsenegative alerts due to bias. 7, 8 Automated implementation of these processes will enable rapid and simultaneous monitoring of many prespecified pairs.
In addition, automated alerting algorithms will be necessary to guide stakeholders to particular associations on which to focus subsequent evaluation. Rules to generate automated alerts must be both sensitive and specific and should generate true-positive alerts quickly to facilitate timely public-health decision making. 9 Many such rules have been proposed for active medical-product-safety monitoring. 10, 11 However, it is not known which algorithms perform best when coupled with semiautomated design and analytic processes for prospective drug-safety surveillance in electronic healthcare data.
In this study, we simulated serially accruing matchedcohort data and compared the performance of alerting algorithms from 5 general classes to determine which are likely to be most useful for active medical-product monitoring in various scenarios. We then used the simulation results to select algorithms that we applied to empirical data for monitoring of rhabdomyolysis among patients newly treated with cerivastatin. Cerivastatin is a cholesterol-lowering drug that was withdrawn from the US market in 2001 because of its association with rhabdomyolysis. 12 We chose this example because it is a universally recognized drug-safety issue.
METHODS

Simulation Study Framework
We simulated data, as they would accrue prospectively for newly marketed medical products in an electronic healthcare database. We used a sequential 1:1 matched-cohort design, and simulated data updating at fixed calendar intervals. In each of 20 sequential calendar intervals, we generated data for 1:1 matched users and nonusers of the monitored product of interest. The sequential matched-cohort approach has previously been used in retrospective electronic healthcare data for pharmacoepidemiologic research during the early marketing period. 13 The matched-cohort design can be deployed rapidly in electronic healthcare data 7 and was found in a simulation study to be more efficient than other approaches for safety surveillance. 14 This design can also easily accommodate semiautomated confounding adjustment strategies that exploit the high-dimensional nature of electronic healthcare data. 15, 16 Such automated variable-selection procedures can inform the construction of confounder summary scores, such as propensity scores 17 or disease risk scores, 18 on which exposed and unexposed patients are matched to balance observed baseline confounders.
The parameters in the simulation study are summarized in a table in eAppendix A (http://links.lww.com/EDE/A555) and the data generating process is summarized in a flow chart in eAppendix B (http://links.lww.com/EDE/A555). We created 60 monitoring scenarios characterized by 15 different expected unexposed event counts {3, 5, 10, 15, 20, 25, 30, 40, 50, 75 , 100, 150, 300, 500, 1000} and by 4 acceptable relative-risk thresholds (ie, ϭ 1, 1.25, 1.5, 2). The event counts reflected the expected total number of events among unexposed patients across the 20 monitoring periods and ranged from extremely rare (ie, 3) up to relatively common adverse drug events (ie, 1000), with respect to the frequency of the outcomes expected to be monitored by Sentinel-like systems. Stakeholders in active safety monitoring systems may use acceptable risk thresholds if they plan to act only on associations of a certain magnitude after a thorough benefitrisk assessment. For example, stakeholders may be interested if an oral hypoglycemic agent increases the relative risk of myocardial infarction by 50% but may determine a priori that a 10% increase in risk would not warrant subsequent action. 19 Thus, an alert generated for an association for which the true relative risk was 1.10 would be a false-positive alert when ϭ 1.5. For each of the 60 combinations of event counts and thresholds, we generated 10,000 sets of 20 sequential cohorts, for a total of 600,000 simulations.
Data Generation
To simulate data for the 600,000 iterations, we first randomly selected the baseline event risk among the unexposed, R0, from a log-normal distribution, lnN(ln͓x͔,0.5), where x was the median expected baseline risk, which equaled the expected event count (eg, 3, …, 1000) divided by the total number of unexposed patients in the 20 cohorts. We used a log-normal distribution so that the median expected total number of events among the unexposed was equal to the expected event count across all scenarios, and therefore the expected total event count in any given scenario was never nonpositive. We used a variance of 0.5 to regulate the right tail of the distribution.
We then selected a true underlying log risk ratio from a skewed-normal distribution, 20 with location of Ϫ0.5, scale of 1, and shape of 5 (the resulting percentiles of the true risk ratio ͓RR true ͔ distribution were 10%, 0.66; 25%, 0.83; 50%, 1.19; 75%, 1.92; 90%, 3.13). We used this distribution to reflect our prior belief that the majority of true underlying risk ratios among scenarios to be monitored in a Sentinel-like system would be just right of unity and asymmetrically distributed, with skewing to the right.
We multiplied R0 by RR true to obtain the underlying event incidence among the exposed, R1, for a given scenario. In each of the 20 sequential cohorts, we then generated the observed numbers of unexposed events from a binomial distribution with probability R0 and number of trials, N, which was the number of exposed patients in the given cohort. We used a separate binomial distribution, with probability R1 and number of trials N, to generate the numbers of observed exposed events in each cohort.
We set the numbers of exposed and unexposed patients (N) to 500 in the first monitoring period and increased N linearly across the 20 periods (to 10,000 in period 20) to model increasing use of the medical product in the early marketing period. We chose a large number of exposed and unexposed patients so that algorithm performance was driven almost exclusively by event counts, recognizing that there are multiple ways to accrue a set number of events (eg, low event rate in a large population, or high event rate in a smaller population).
Alerting Rules
We applied 10 groups of alerting rules, comprising 93 algorithm configurations, from 5 general classes, to each of the 600,000 individual monitoring scenarios. The 5 classes of rules comprised naïve type I error-based approaches, group-sequential monitoring methods, 21 the maximum-sequential-probability ratio test, 10,22,23 statistical-process control rules, 24, 25 and disproportionality measures. 26 The algorithms are described in eAppendix C (http://links.lww.com/EDE/A555), and the specific construction and parameter values of each of the 93 algorithms are detailed in Table 1 .
Performance Evaluation
In each scenario, each of the 93 algorithm configurations had up to 20 opportunities to generate an alert. As described in Table 1 , some algorithms used period-specific data as inputs (ie, data from individual data cuts), whereas most used cumulative data. For a particular scenario, the cumulative cohort in any given period comprised all patients in prior cohorts up to and including the cohort for that period. In each scenario, we recorded whether each algorithm generated an alert, in which period alerting first occurred, and whether a true underlying causal relation of interest existed (ie, RR true Ͼ ). From this, we calculated general operating characteristics, including each algorithm's overall sensitivity (ie, the proportion of scenarios in which RR true Ͼ that the algorithm signaled) and specificity (ie, the proportion of scenarios in which RR true Յ that the algorithm did not signal). We plotted overall sensitivity and 1 Ϫ (overall specificity) on a receiver operating characteristic curve (ROC) for each group of algorithms. As we have previously argued, 14 comparisons of alerting-rule performance in prospective monitoring should consider time to alerting because conventional measures of sensitivity and specificity can misrepresent the public health importance of earlier versus later alerting. 2 Therefore, we also computed event-based performance, which is a weighted average of event-based sensitivity and event-based specificity that accounts for time to alerting and accommodates a weight (w) reflecting user-specified trade-offs between the relative costs of false-positives (eg, patients discontinue needed medication, or effective drugs are withdrawn from the market) versus false-negatives (eg, patients continue to be exposed to products that cause serious adverse events). Choosing w is analogous to choosing a cut point on an ROC curve. We provide a description of the metric in eAppendix D (http://links.lww.com/EDE/A555). Finally, we examined the extent to which the algorithms' relative performance varied by selecting different w values, and we examined variation in relative performance across the range of expected event frequencies.
Application to Empirical Data
We used the simulation results to select algorithms that we then applied to empirical monitoring of cerivastatininduced rhabdomyolysis. Cerivastatin is a cholesterol-lowering drug that was withdrawn from the US market in 2001 because of its association with rhabdomyolysis, a severe condition characterized by muscle breakdown. 12 We determined whether and when the selected algorithms would have generated alerts for this association had it been processed in an active monitoring system based on the sequential matched-FIGURE 1. Receiver-operating-characteristic curves based on overall sensitivity and overall specificity for 10 groups of alerting algorithms across all 600,000 simulated scenarios. Each arc comprises multiple points representing the various parameter values (e.g. different values of p, ␣, etc.) for each alerting algorithm group, as described in Table 1 . Overall sensitivity and overall specificity do not incorporate time to alerting. , algorithm sensitivity increases moving down the box (e.g. p increases, ␣ increases, etc). A, The value for the weight defining the preference between sensitivity versus specificity in the evaluation metric increases from left to right from 0.02 (indicating very strong preference for specificity) to 0.30 (indicating very slight preference for specificity). B, The expected event frequency increases from left to right from 3 to 1000 and the preference weight (w) is held constant at w ϭ 0.10 across all cells.
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Selecting Alerting Rules for Active Safety Monitoring cohort design. We summarize the data sources and the methods in eAppendix E (http://links.lww.com/EDE/A555).
RESULTS
Simulations
Among 600,000 scenarios, 370,405 (62%) were scenarios in which a true causal relation existed (ie, RR true Ͼ 1.0); of these, 251,879 (42%) were scenarios in which RR true Ͼ (ie, these were scenarios in which the true underlying risk ratio was greater than the signaling threshold). Figure 1 displays the overall sensitivity and 1 Ϫ (overall specificity) for each group of algorithms across their parameter values. Overall sensitivities ranged from 0.1859 (group 7, X ϭ 11; 11 consecutive period-specific estimates with values of p Ͻ 0.1587) to 0.9534 (group 9, X ϭ 2; 2 consecutive cumulative effect estimates above the threshold, ), and specificities ranged from 0.5759 (group 9, X ϭ 2) to 0.9999 (group 10; X ϭ 11; 11 consecutive period-specific estimates above the threshold, ) across all 600,000 scenarios.
After accounting for time to alerting using an eventbased performance metric, 9 the relative performance of the algorithms varied by the chosen weight (w), reflecting preference for sensitivity versus specificity ( Fig. 2A) , by the expected event frequency (Fig. 2B) , and by the alerting threshold (eFigure 2, http://links.lww.com/EDE/A555). In general, the most sensitive algorithms in a group (ie, those at the bottom of each box) did not perform relatively well. In particular, naïve nominal type 1 error approaches (group 1) generally performed poorly when large values of p were used, regardless of the weight (w) assigned. At lower event frequencies, ␣-based approaches with relatively large ␣ or p values tended to perform better than other approaches (Fig.  2B ). However, for frequent events, the statistical process control and disproportionality approaches tended to perform better than ␣-based algorithms. To assess empirical power of the algorithms, we compared their overall sensitivities, which varied widely both between and within groups of algorithms, with a range of 0.13 to 0.77 (eFigure 3, http://links.lww.com/EDE/A555).
Simulation results from all 60 scenarios are retrievable through an online program at www.drugepi.org. In Table 2 , we present the operating characteristics for the algorithms that attained highest event-based performance at 3 weights (w) among scenarios resembling monitoring of cerivastatin and rhabdomyolysis, where the expected event count was 3 and the alerting threshold was ϭ 1.0. The top 2 algorithms a Listed are the 3 algorithms with the highest event-based performance for each of 3 values of w (defined below) among the 10,000 simulation scenarios that were chosen to resemble monitoring for cerivastatin-induced rhabdomyolysis in which we expected to observe approximately 3 events among the unexposed and in which any excess relative risk among the exposed was of interest for alerting. b w is a user-defined weight that reflects trade offs between the costs of false-negatives and false-positives; smaller weights reflect higher relative costs of false-positives. c Event-based sensitivity is the proportion of observed exposed events in alertworthy scenarios (ie, scenarios in which a safety issue of interest exists; where the true underlying risk ratio Ն the alerting threshold) that occurred after the given algorithm generated an alert. d Event-based specificity is the proportion of observed exposed events in nonalertworthy scenarios (ie, scenarios in which no safety issue of interest exists; where the true underlying risk ratio Ͻ the alerting threshold) that occurred before or in the absence of an alert by the given algorithm. e Event-based performance (EBP), which is an average of event-based sensitivity and event-based specificity, weighted by w, such that EBP ϭ (event-based sensitivity) ϫ w ϩ (event-based specificity) ϫ (1 Ϫ w).
were the same at w ϭ 0.05 and w ϭ 0.10. Alpha-based approaches, particularly the nominal type I error-based algorithms and group-sequential methods, generally performed best in these scenarios. Overall, these 7 alerting algorithms had very high specificity (range, 0.9696 -0.9958)-reflecting, in part, the small weights that were chosen to minimize the likelihood of false-positive alerting. We applied all 7 algorithms to the cerivastatin empirical data.
Application to Cerivastatin and Rhabdomyolysis
We monitored initiators of cerivastatin from 1998, when prescriptions for the drug began appearing in the databases, to mid-2001, when the drug was withdrawn from the US market. During this time, we observed 6 cases of rhabdomyolysis and severe myopathies among 3530 pairs of propensity-score-matched cerivastatin and atorvastatin initiators, who contributed a total of 4294 person-years of followup. All 6 events occurred among patients exposed to cerivastatin ( Fig. 3 ). All 7 selected algorithms generated alerts by the end of the 13th monitoring period, corresponding to June 2001-2 months before cerivastatin was withdrawn from the market. One algorithm generated an alert as early as the close of the 10th monitoring period (September 2000). In Figure 3 , we included several milestones in the history of this example, including the completion of an observational study by cerivastatin's manufacturer that failed to detect the association. 12 At the end of the entire monitoring time frame, the estimated rate difference was 3.0 events (95% confidence interval ͓CI͔: 0.6 -5.4) per 1000 person-years.
DISCUSSION
In a simulated, sequential, matched-cohort framework, we observed substantial variation in performance of algorithms that could be used to generate safety alerts in prospective medical product monitoring systems, such as the FDA's Sentinel System. Relative performance depended on the frequency of events in each set of simulations, whether an alerting threshold was used and its magnitude, and the tradeoffs in costs between false-positive and false-negative alerting, as reflected by values of a weight in the performance metric. No single algorithm performed best in all scenarios. Alerting-algorithm selection should be tailored to certain features of a monitoring scenario, particularly the expected event frequencies and trade-offs between false-positive and false-negative alerting.
When event frequencies were low, ␣-based approaches with large ␣ values tended to perform relatively better than other algorithms. When the expected event frequencies were high, statistical-process-control and disproportionality approaches tended to perform better. This is due, in part, to the built-in delays in alerting, which prevent these algorithms from generating chance alerts early in the early monitoring period. For example, an algorithm that requires information from 5 consecutive monitoring periods to generate an alert, by definition cannot generate an alert until at least the fifth monitoring period.
The algorithms' relative performance also depended on whether an alerting threshold was used and, if so, the value of this threshold. We compared the algorithms across 4 possible relative-risk threshold values: 1, 1.25, 1.5, and 2. A threshold FIGURE 3. A reproduction of prospective monitoring of cerivastatin and rhabdomyolysis using retrospective data from two electronic healthcare databases from 1998 to 2001. In each monitoring period the numbers are updated in a cumulative fashion based on the data that became available during the corresponding calendar quarter. The black text below the table shows when each milestone in the history of this example occurred in relation to our monitoring periods. 12 Epidemiology • Volume 23, Number 2, March 2012
Selecting Alerting Rules for Active Safety Monitoring of 1 implies that any indication of harm is of interest, regardless of how small. In some scenarios, stakeholders may decide that associations below a certain magnitude are not actionable. For example, stakeholders may decide that up to a 20% increased incidence of cardiovascular events among users of a particular oral hypoglycemic agent is acceptable. 19 By using an alerting threshold, the monitoring system can be programmed to generate alerts only if the observed association exceeds the specified acceptable risk threshold. The selection of a threshold should be based on a thorough benefit-risk assessment that considers, among many inputs, the severity of the monitored event, the availability of alternative treatments, the relative benefit of the monitored product compared with the alternatives, other safety considerations, and the background incidence of the monitored outcome. We cannot recommend which threshold should be used in a particular monitoring scenario; we have made the simulated results for all 60 scenario types, defined by 15 expected event frequencies and by 4 alerting thresholds, available in an online lookup table (www.drugepi.org). We used the simulation results to guide selection of the most appropriate algorithms for empirical monitoring of cerivastatin-induced rhabdomyolysis in 2 electronic healthcare databases. Over the entire monitoring time frame, we observed a rate difference of 3.0 events (95% CI ϭ 0.6 -5.4) per 1000 person-years, which is consistent with estimates from formal pharmacoepidemiologic studies. 27 Each of the chosen algorithms generated alerts before cerivastatin was withdrawn from the market. It is important to note that not all algorithms would have generated alerts in the empirical data. For example, the nominal value of p at the end of the monitoring time frame was 0.0114, which was not small enough to generate alerts for many of the ␣-based algorithms, including 4 of the nominal type 1 error approaches, 7 of the Pocock-like rules, and 5 of the O'Brien-Fleming-like algorithms. In addition, several of the algorithms that were not selected (ie, the 3 most sensitive disproportionality measures) would have generated alerts earlier than each of the selected algorithms. However, the simulation results are intended to guide algorithm selection after balancing user-specified preferences for sensitivity and specificity. Thus, the more sensitive algorithms would have generated more timely alerts in this case but would be more likely to generate false-positives in similar scenarios that lack true safety issues. Of the selected algorithms, one generated an alert after the addition of data from the third quarter of 2000, after only 3 observed events and nearly a year before cerivastatin was withdrawn from the market. The other algorithms generated alerts based on either 4 or 5 observed events and still before market withdrawal.
The algorithms we evaluated are not intended to prompt regulatory decisions, but rather to alert stakeholders to patterns that may warrant closer scrutiny. In a full-scale active monitoring system, stakeholders may simultaneously monitor hundreds or thousands of potential associations, which will be too burdensome for continuous human processing. However, the features of a monitoring scenario that would prompt a reviewer to take a closer look at a particular association can be encoded into automated alerting rules. In this study, we compared 10 groups of rules from 5 general classes of existing sequential-monitoring approaches, coupled with 4 alerting thresholds. Future research should focus on incorporating other features of a monitoring scenario (eg, requiring a certain number of events before alerting) and employing combinations of existing rules. For example, a rule could be devised such that alerting would occur only if at least 4 of the 5 alerting algorithms fired, the observed risk ratio was greater than a prespecified threshold, and more than a prespecified number of events were observed.
We made many assumptions that may limit the generalizability of our simulation study. First, we generated data assuming an absence of residual and unmeasured confounding and an absence of misclassification of exposure and outcomes, which is likely untenable in electronic healthcare data. However, because all of the alerting algorithms used the same basic exposure and outcome information as inputs, this assumption is not likely to affect their relative performance. In addition, an alerting threshold can allow users to incorporate confounding and misclassification that may bias effect estimates upward. For example, one may not be interested in relative effects of less than 1.25 because of concerns that they are confounded. Using an alerting threshold of 1.25 effectively redefines the reference standard by considering only estimates above this threshold. We allowed algorithms to generate alerts when their statistical criteria were fulfilled only if the observed relative frequency of exposed and unexposed events was above a predefined threshold. Most of the algorithms are configured to test the null hypothesis that the observed outcome frequency among the exposed is equal to that among the unexposed. It is possible that, when a threshold is used, algorithms may perform better if they are constructed to test the threshold as an alternative hypothesis. However, Kulldorff and colleagues 23 have demonstrated the practical limitations of alternative hypotheses in sequential monitoring, and the sensitivity of monitoring results to the choice of alternative hypotheses. Although coupling algorithms that test the null hypothesis with the threshold criterion is one way around this issue, the optimal combination of alerting algorithms and thresholds for prospective safety monitoring requires further research.
We also assumed in the simulation study that hypothetical events occurred instantaneously, such that loss-to-follow-up could not occur and that all outcome information was available at the time of cohort formation. Many alternative modeling approaches are possible, including ones that incorporate long induction times, time-varying hazards, and infor-mative censoring. We chose a much simpler approach as a starting point because active surveillance systems (such as Sentinel) that rely on electronic healthcare data may not be useful for identifying certain types of effects, such as longterm carcinogenic effects. However, the approach we simulated is also consistent with a setting in which the distribution of matched patients is uniform across the monitoring time frame, but the event risk increases over time. We simulated the data such that the number of matched exposed and unexposed patients and the number of events increased linearly across the 20 monitoring periods, to model data as they would stream through an active monitoring system for a newly marketed product and with data updates that occur at regular intervals defined by calendar time. It may be possible that other approaches, such as adding new data at the accrual of a set number of monitored events (similar to monitoring approaches in clinical trials) may offer advantages for statistical efficiency. The relative performance of algorithms in this setting may differ from the setting that we considered; this should be evaluated in future work. However, across a large distributed-data network in which many exposure and outcome pairs will be simultaneously monitored, synchronized querying at fixed calendar dates is likely the most logistically feasible approach.
Finally, we assumed a uniform event rate across the 20 cohorts in each scenario, which likely favors approaches that rely on cumulative data. Modification by time may occur if types of patients who use the treatments evolve with time, and these characteristics are effect-measure modifiers. This may result in scenarios in which no true safety issue exists early in monitoring but arises in subsequent cohorts. Algorithms that use cumulative data may be insensitive to the late-appearing safety issue because of the prior accumulation of nonsuggestive data. Algorithms that rely on period-specific estimates may be more capable of identifying the safety issue in a more timely manner, but this issue requires additional research.
Despite their limitations, the simulation results were useful in guiding the selection of algorithms that were then able to detect cerivastatin-induced rhabdomyolysis, a wellknown drug-safety issue. A major concern of large-scale active monitoring systems is that they will generate an intractably large number of false-positive alerts. We plan to expand our approach to several empirical examples for which a generated alert would be a false-positive. The biggest threat to false positivity in a Sentinel-like system using electronic healthcare data is confounding by indication and other biases that arise from observational data. Our approach relies on a sequential-matched-cohort design, focuses on new users of the drug of interest, and matches them to users of an active comparator using propensity-score methods. Propensityscore matching restricts patients exposed to the monitored drug to those with values that overlap with the distribution of scores for those exposed to the comparator drug. Thus, patients at the extremes of the propensity-score distributions may be excluded from analyses, yet they may be particularly susceptible to the drug-related event of interest. We suggest exploring event rates among these patients in sensitivity analyses. However, implicit restriction by matching can increase validity if observations in the tails of the distribution reflect the presence of unmeasured confounding. 28 The propensity-score-matched cohort approach offers several additional advantages for safety monitoring: (1) it enables application of many alerting algorithms without further adjustments; (2) it allows for monitoring of multiple outcomes within the same matched cohorts; and (3) it focuses on patients who are exchangeable with patients exposed to the active comparator, thereby reducing confounding and mitigating the burden of false positivity. 7 Moreover, for newly marketed drugs, there are usually many more patients exposed to the active comparator, allowing for near-complete matching of patients exposed to the new drug.
In conclusion, the performance of existing alerting algorithms for prospective medical-product-safety monitoring varies when applied to a sequential, matched cohort framework for active surveillance. Algorithm selection for application to empirical monitoring should consider the expected frequency of the monitored event, trade-offs between sensitivity and specificity, and whether an alerting threshold should be used. Simulation results can help inform algorithm selection. By applying the results of the simulation study, as one component of an approach to prospective medical-product monitoring, we detected rhabdomyolysis associated with cerivastatin before the drug was withdrawn from the market.
